BHC(SH:600721) Xin Lang Cai Jing·2025-09-22 05:57Core Viewpoint - Baohua Pharmaceutical's stock has experienced fluctuations, with a notable decline of 2.08% on September 22, 2023, amidst significant trading activity and a year-to-date increase of 42.64% [1] Company Overview - Baohua Pharmaceutical, established on June 21, 1996, and listed on June 26, 1996, is located in Urumqi, Xinjiang. The company specializes in early drug discovery, CMC development, clinical trials, registration, and various pharmaceutical services [2] - The company's revenue composition includes 49.39% from clinical trials, 42.67% from pharmaceutical R&D and consistency evaluation, 6.69% from leasing and property services, and 0.94% from other income [2] - As of June 30, 2023, the number of shareholders is 30,000, a decrease of 26.42%, with an average of 12,799 circulating shares per person, an increase of 35.95% [2] Financial Performance - For the first half of 2023, Baohua Pharmaceutical reported revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to shareholders of 25.48 million yuan, up 12.45% year-on-year [2] - The company has cumulatively distributed 6.1275 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]